As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.
16 Analysts have issued a Halozyme Therapeutics, Inc. forecast:
16 Analysts have issued a Halozyme Therapeutics, Inc. forecast:
Jun '25 |
+/-
%
|
||
Revenue | 1,179 1,179 |
35%
35%
|
|
Gross Profit | 992 992 |
42%
42%
|
|
EBITDA | 754 754 |
59%
59%
|
EBIT (Operating Income) EBIT | 683 683 |
70%
70%
|
Net Profit | 557 557 |
65%
65%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Helen Torley |
Employees | 350 |
Founded | 1998 |
Website | www.halozyme.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.